Investors are waking up to the risk of litigation against the makers of Zantac, once a blockbuster treatment for heartburn. All of a sudden, GSK Plc's decision to spin off rather than sell its consumer-healthcare business, Haleon Plc, is looking costly ...
VIEW MORE : https://bit.ly/1breakingnews
